Revvity sold a little more and made a little less from it.

Revenue for the six months ended July 5 rose 1.3% to $729.7 million from the comparable period a year earlier. Operating income fell 1.6%, and operating margin narrowed to 12.2% from 12.6%.

Then comes the accounting oddity with a cash-flow twist: operating cash flow rose 17%. The business generated $307.2 million from operations, even as net income slipped 3.9%.

The gross-profit line explains part of the split. Revvity said the six-month gross-margin improvement came from tariff refunds and a shift in product mix:

"As a percentage of revenue, cost of revenue decreased to 44.2% for the six months ended July 5, 2026, from 44.5% for the six months ended June 29, 2025, resulting in an increase in gross margin of 40 basis points to 55.8% from 55.5%, primarily due to tariff refunds and product mix shift."

Revvity, 10-Q, Aug. 11, 2026

That is a useful lift, but it did not flow through to operating income. Management attributed the lower segment margin to strategic spending on software and new products, along with the extra fiscal week in the six-month period:

"Segment operating margin decreased 150 basis points in the six months ended July 5, 2026, as compared to the six months ended June 29, 2025, primarily due to strategic investments in software and new product development and impact of the extra fiscal week in the six months ended July 5, 2026."

Revvity, 10-Q, Aug. 11, 2026

So the filing presents two versions of Revvity at once. Gross margin improved, but operating expenses absorbed the benefit as the company invested. Diagnostics revenue rose 4.7%, while Life Sciences revenue fell 2.0%, leaving the consolidated top line nearly flat.

The cash improvement also came with a balance-sheet detail worth keeping in view. Inventory declined 2.6%, while accounts receivable rose 7.3%, a faster pace than revenue. Capex fell 11.5%, which reduced the cash required for investment, but the filing does not say why receivables grew.

Fewer shares helped the per-share math: diluted shares fell 5.0%, allowing diluted EPS to rise 2.2% even as net income declined. Revvity ended with more cash than a year earlier, and the stock closed at $116.02 on Aug. 10, up 1.2% that day.

The longer record makes the latest six months look less like a return to rapid expansion than another small step in a low-growth business. Revvity's annual revenue reached $2.9 billion in 2025, up 3.7%, while operating margin was 12.5%. The current period's 1.3% sales growth and 12.2% operating margin sit close to that recent pattern, with cash conversion doing more of the visible work.

Revvity's next 10-Q will put a fresh number on gross margin and disclose whether tariff refunds remain part of that explanation. For now, the trade-off is simple enough: sales inched forward, while cash picked up the tab.

Revvity's six-month filing shows modest sales growth, lower operating income, and higher operating cash flow.